About this Session:
Febrile neutropenia remains the most common and costliest complication of cancer therapy with over $11 billion spent every year on its management. The introduction of Liberty, the world’s first at-home blood count analyzer for cancer patients has opened up a wealth of new opportunities to address febrile neutropenia care pathways. This talk introduces how world-leading institutions and oncologists are utilizing Liberty to enhance patient care in relation to this life-threatening complication.